Literature DB >> 8164559

Urinary disorders associated with cisapride. Adverse Drug Reactions Advisory Committee.

I W Boyd, A P Rohan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8164559

Source DB:  PubMed          Journal:  Med J Aust        ISSN： 0025-729X            Impact factor:   7.738


× No keyword cloud information.
  6 in total

1.  Pharmacological characterization of the human 5-HT(4(d)) receptor splice variant stably expressed in Chinese hamster ovary cells.

Authors:  J Mialet; I Berque-Bestel; S Sicsic; M Langlois; R Fischmeister; F Lezoualc'h
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

2.  Population pharmacokinetics of enterally administered cisapride in young infants with gastro-oesophageal reflux disease.

Authors:  Y Preechagoon; B Charles; V Piotrovskij; T Donovan; A Van Peer
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

3.  The effects of bethanechol and cisapride on urodynamic parameters in patients undergoing radical hysterectomy for cervical cancer. A randomized, double-blind, placebo-controlled study.

Authors:  Alberto P Madeiro; Andréa C Rufino; Marair G F Sartori; Edmund C Baracat; Geraldo Rodrigues De Lima; Manoel J B C Girão
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2005-06-14

4.  Piboserod (SB 207266), a selective 5-HT4 receptor antagonist, reduces serotonin potentiation of neurally-mediated contractile responses of human detrusor muscle.

Authors:  B Darblade; D Behr-Roussel; D Gorny; T Lebret; G Benoit; J-P Hieble; D Brooks; L Alexandre; F Giuliano
Journal:  World J Urol       Date:  2005-05-18       Impact factor: 4.226

5.  Neural 5-HT4 receptors in the human isolated detrusor muscle: effects of indole, benzimidazolone and substituted benzamide agonists and antagonists.

Authors:  S M Candura; E Messori; G P Franceschetti; G D'Agostino; D Vicini; M Tagliani; M Tonini
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

Review 6.  A risk-benefit assessment of cisapride in the treatment of gastrointestinal disorders.

Authors:  J Tack; G Coremans; J Janssens
Journal:  Drug Saf       Date:  1995-06       Impact factor: 5.606
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.